Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
J Clin Oncol
; 35(3): 343-351, 2017 Jan 20.
Article
in En
| MEDLINE
| ID: mdl-27918718
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
DNA Modification Methylases
/
Antineoplastic Combined Chemotherapy Protocols
/
Biomarkers, Tumor
/
Hepatocyte Growth Factor
/
Glioblastoma
/
DNA Methylation
/
Angiogenesis Inhibitors
/
Tumor Suppressor Proteins
/
DNA Repair Enzymes
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Clin Oncol
Year:
2017
Document type:
Article
Country of publication:
United States